KR100795870B1 - 라소폭시펜의 경피적 송달 - Google Patents

라소폭시펜의 경피적 송달 Download PDF

Info

Publication number
KR100795870B1
KR100795870B1 KR1020027001424A KR20027001424A KR100795870B1 KR 100795870 B1 KR100795870 B1 KR 100795870B1 KR 1020027001424 A KR1020027001424 A KR 1020027001424A KR 20027001424 A KR20027001424 A KR 20027001424A KR 100795870 B1 KR100795870 B1 KR 100795870B1
Authority
KR
South Korea
Prior art keywords
effective amount
drug
matrix
transdermal
lasopoxifen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027001424A
Other languages
English (en)
Korean (ko)
Other versions
KR20030025219A (ko
Inventor
픽스타드데이비드
콴다니
Original Assignee
왓슨 파머수티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 왓슨 파머수티컬즈, 인코포레이티드 filed Critical 왓슨 파머수티컬즈, 인코포레이티드
Publication of KR20030025219A publication Critical patent/KR20030025219A/ko
Application granted granted Critical
Publication of KR100795870B1 publication Critical patent/KR100795870B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020027001424A 2000-06-01 2001-05-31 라소폭시펜의 경피적 송달 Expired - Fee Related KR100795870B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20878900P 2000-06-01 2000-06-01
US60/208,789 2000-06-01
PCT/US2001/017567 WO2001091724A2 (en) 2000-06-01 2001-05-31 Transdermal delivery of lasofoxifene

Publications (2)

Publication Number Publication Date
KR20030025219A KR20030025219A (ko) 2003-03-28
KR100795870B1 true KR100795870B1 (ko) 2008-01-21

Family

ID=22776068

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027001424A Expired - Fee Related KR100795870B1 (ko) 2000-06-01 2001-05-31 라소폭시펜의 경피적 송달

Country Status (24)

Country Link
US (1) US20020037311A1 (enExample)
EP (1) EP1229909B1 (enExample)
JP (1) JP2003534368A (enExample)
KR (1) KR100795870B1 (enExample)
CN (1) CN1400897A (enExample)
AT (1) ATE253910T1 (enExample)
AU (2) AU785199B2 (enExample)
BR (1) BR0106680A (enExample)
CA (1) CA2380769A1 (enExample)
CZ (1) CZ2002488A3 (enExample)
DE (1) DE60101206T2 (enExample)
DK (1) DK1229909T3 (enExample)
ES (1) ES2210168T3 (enExample)
HK (1) HK1052472A1 (enExample)
HU (1) HUP0202592A3 (enExample)
IL (2) IL147640A0 (enExample)
MX (1) MXPA02001152A (enExample)
NZ (1) NZ516582A (enExample)
PL (1) PL201222B1 (enExample)
PT (1) PT1229909E (enExample)
RU (1) RU2328276C2 (enExample)
TR (1) TR200400241T4 (enExample)
WO (1) WO2001091724A2 (enExample)
ZA (1) ZA200200519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7804912B2 (en) * 2004-09-23 2010-09-28 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
US7564908B2 (en) * 2004-09-23 2009-07-21 Motorola, Inc. Method and apparatus for encryption of over-the-air communications in a wireless communication system
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
US20100292660A1 (en) * 2007-07-10 2010-11-18 Agis Kydonieus Dermal delivery device with ultrasonic weld
BRPI0814697B8 (pt) * 2007-07-10 2021-05-25 Agile Therapeutics Inc dispositivo de liberação de fármacos
US20140378424A1 (en) * 2011-12-30 2014-12-25 Rosscreening, Inc. Estrogen receptor modulators for reducing body weight
CN103751138A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种含酒石酸拉索昔芬的口腔崩解片及其制备方法
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN103830207A (zh) * 2014-03-14 2014-06-04 崔书豪 一种酒石酸拉索昔芬贴膏剂
PL3325080T3 (pl) * 2015-07-24 2022-01-24 Sorrento Therapeutics, Inc. Sposoby lepszego dostarczania środków czynnych do guzów
CN107949418B (zh) * 2015-07-24 2024-07-02 索伦托治疗有限公司 用于活性剂的淋巴递送的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021656A1 (en) * 1995-01-09 1996-07-18 Pfizer, Inc. Estrogen agonists/antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
CN1170360A (zh) * 1994-12-21 1998-01-14 瑟垃技术有限公司 具有粘性贴面和剥离密封圆片的经皮输送系统
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021656A1 (en) * 1995-01-09 1996-07-18 Pfizer, Inc. Estrogen agonists/antagonists

Also Published As

Publication number Publication date
HUP0202592A2 (hu) 2002-12-28
JP2003534368A (ja) 2003-11-18
KR20030025219A (ko) 2003-03-28
HK1052472A1 (zh) 2003-09-19
TR200400241T4 (tr) 2004-04-21
AU2007200426A1 (en) 2007-02-22
PL201222B1 (pl) 2009-03-31
DK1229909T3 (da) 2004-03-15
EP1229909A2 (en) 2002-08-14
DE60101206D1 (de) 2003-12-18
US20020037311A1 (en) 2002-03-28
MXPA02001152A (es) 2002-08-20
ES2210168T3 (es) 2004-07-01
CA2380769A1 (en) 2001-12-06
WO2001091724A2 (en) 2001-12-06
RU2328276C2 (ru) 2008-07-10
EP1229909B1 (en) 2003-11-12
BR0106680A (pt) 2002-04-30
AU785199B2 (en) 2006-11-02
HUP0202592A3 (en) 2003-07-28
DE60101206T2 (de) 2004-09-02
IL147640A (en) 2007-03-08
CZ2002488A3 (cs) 2002-06-12
PT1229909E (pt) 2004-04-30
CN1400897A (zh) 2003-03-05
ZA200200519B (en) 2003-04-22
NZ516582A (en) 2004-08-27
IL147640A0 (en) 2002-08-14
WO2001091724A3 (en) 2002-05-30
AU6523501A (en) 2001-12-11
ATE253910T1 (de) 2003-11-15
PL354628A1 (en) 2004-02-09
RU2002105378A (ru) 2003-11-10

Similar Documents

Publication Publication Date Title
KR100505171B1 (ko) 스테로이드안정성을개선하기위한약물수송조성물
AU2007200426A1 (en) Transdermal delivery of lasofoxifene
KR100392435B1 (ko) 성스테로이드를함유하는경피치료시스템
AU760588B2 (en) Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
CA2263334A1 (en) Fatty acid esters of lactic acid salts as permeation enhancers
JP2001527581A (ja) メントの経皮投与
WO2005060540A2 (en) Norethindrone sustained release transdermal formulation
WO1991005529A1 (en) Drug delivery systems and matrix therefor
JP3043071B2 (ja) エストロゲンを含む経皮的投与装置
TWI298253B (en) Transdermal delivery of lasofoxifene
US20040037873A1 (en) Norethindrone sustained release formulations and methods associated therewith
HK1066724B (en) Drug delivery compositions for improved stability of steroids

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110112

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110112

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000